Compare HLF & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLF | ORKA |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | HLF | ORKA |
|---|---|---|
| Price | $14.23 | $27.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $15.50 | ★ $48.20 |
| AVG Volume (30 Days) | ★ 2.1M | 719.0K |
| Earning Date | 02-18-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.95 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $4,961,900,000.00 | N/A |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | $4.53 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.04 | $5.49 |
| 52 Week High | $15.17 | $32.64 |
| Indicator | HLF | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 63.32 | 44.15 |
| Support Level | $12.68 | $25.23 |
| Resistance Level | $14.21 | $32.64 |
| Average True Range (ATR) | 0.55 | 2.15 |
| MACD | -0.13 | -0.55 |
| Stochastic Oscillator | 77.73 | 34.55 |
Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.